Royalty Pharma

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Royalty Pharma reports robust Q4 performance and strategic growth outlook

Royalty Pharma's Q4 2022 earnings call highlighted strong financial performance, efficient cash flow management, and strategic acquisitions. While facing challenges in certain product sales trajectories and market conditions, the company remains focused on innovation and long-term success in the life sciences industry.

Royalty Pharma reports robust Q1 performance and raises capital deployment guidance

Royalty Pharma's Q1 2023 earnings call highlighted strong financial performance, strategic portfolio expansion, and disciplined capital deployment. The company's robust financial health, selective investment approach, and optimistic outlook on market opportunities position them for continued growth. Challenges in deal flow prediction and balancing investments underscore the need for strategic planning and adaptability in a competitive market landscape.

Royalty Pharma (RPRX) reports robust Q2 results amidst regulatory challenges

Royalty Pharma's Q2 performance reflects resilience and growth, supported by strategic initiatives and strong financial metrics. While facing challenges related to regulatory impacts and investor sentiment, the company is focused on leveraging opportunities in attracting investors, educating about its business model, and expanding capital deployment for future growth.

Royalty Pharma reports robust Q3 performance and optimistic growth outlook

Royalty Pharma's Q3 earnings call showcased strong financial performance, active capital allocation, and a focus on shareholder value creation. The company's robust financial model, emphasis on tailored solutions, and optimism about portfolio growth position it well for future opportunities.

Royalty Pharma reports robust 2023 performance and outlines growth strategies

Royalty Pharma's strong performance in 2023 and strategic acquisitions position the company for continued growth in 2024.
Challenges include legal uncertainties and managing shareholder turnover, while opportunities exist in innovative investments and enhanced investor relations.
The company's focus on transparency and attracting long-term investors underscores its commitment to sustainable growth.

Royalty Pharma reports strong Q1 growth and strategic acquisitions

Royalty Pharma's Q1 performance reflects growth and strategic acquisitions, positioning the company for future success.
While facing challenges related to safety concerns and short-term portfolio fluctuations, Royalty Pharma remains focused on growth.
The company's emphasis on identifying high-potential drugs and upcoming milestones underscores a promising outlook for investors.

Royalty Pharma reports robust Q3 growth and eyes innovative therapies

Royalty Pharma's Q3 performance reflects strong growth and strategic decision-making, positioning the company for continued success.
Despite challenges in market penetration and administration, Royalty Pharma remains optimistic about its growth prospects and innovative therapies.
The company's focus on synthetic royalties, strategic acquisitions, and financial discipline underpin its resilience and potential for future expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the Company's Class A ordinary shares in an underwritten public offering. The selling shareholders are expected to grant the underwriters an option to purchase up to 2,601,455 additional Class A ordinary shares. The Company will not receive any of the proceeds from the sale of its Class A ordinary shares by the selling shareholders.

Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders

Dun & Bradstreet Holdings

Renaissance International IPO ETF

Lemonade

Global X Nasdaq 100 Covered Call & Growth ETF

Direxion Work From Home ETF

SPDR S&P 500 ESG ETF

IPO stocks offer all sorts of risks and rewards. Here are seven new stocks to buy that represent the best of both worlds.

The 7 Best New Stocks From 2020 to Buy Now

Alexion Pharma

Biogen

Gilead Sciences

Regeneron Pharmaceuticals

Although markets have pulled back so far in September, many are viewing this as a technical correction, as the markets ran very hot in a very strong August.

5 Very Undervalued Large Cap Biotech Stocks That Could Explode in 2021

Royalty Pharma Discounted Despite High ROIC Business Model

NEW YORK, Sept.  02, 2020  (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”):

Royalty Pharma Announces Closing of $6.0 Billion Senior Unsecured Notes

Ping Identity Holding Corp

Rocket Companies, Inc.

Rackspace Technology, Inc.

ZoomInfo Technologies

2020 is looking a whole lot like 1999, as technology initial public offerings that made little or no money came out and rocketed higher.

5 Recent IPOs Still Have Massive Upside Potential

Royalty Pharma stock has faded after rallying immediately after its IPO. With valuation more reasonable, RPRX has a solid long-term case.

Royalty Pharma Stock Should Be Moving Off Your Watchlist

You'll have a rare chance to capitalize on two highly lucrative markets as Royalty Pharma stock profits from drugmakers in a different way.
The post Royalty Pharma Is the Left-Field Investment You’re Missing Out On appeared first on InvestorPlace.

Royalty Pharma Is the Left-Field Investment You’re Missing Out On

Royalty Pharma PLC RPRX, +1.81% priced a $6 billion bond offering on Tuesday, joining the many companies issuing record levels of debt during the pandemic.

Royalty Pharma prices $6 billion bond deal that is its first as a public company

NEW YORK, Aug.  25, 2020  (GLOBE NEWSWIRE) -- Royalty Pharma plc announced today that it has priced an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”):

Royalty Pharma Announces Pricing of $6.0 Billion Senior Unsecured Notes

Royalty Pharma's cash flow growth will power the stock higher. If cash flow continues at this pace, RPRX stock could rise by at least 88% over the next three years.

Royalty Pharma’s Cash Flow Growth Will Power the Stock Higher

NEW YORK, Aug.  19, 2020  (GLOBE NEWSWIRE) -- Royalty Pharma plc announced today that it intends to offer, subject to market and other conditions, senior unsecured notes in multiple tranches (the “Notes”) in a private offering exempt from registration in accordance with Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd.

Royalty Pharma Announces Launch of Senior Notes Offering

Royalty Pharma - Starting To Look More Compelling

Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q2 2020 Results - Earnings Call Transcript

Royalty Pharma PLC (NASDAQ: RPRX) had a big initial public offering this summer, and it also reported earnings on Wednesday morning.

How Is Royalty Pharma Poised After Earnings?

NEW YORK, Aug.  12, 2020  (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2020 and introduced full-year 2020 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).

Royalty Pharma Reports Second Quarter 2020 Results

Applied Materials

Cisco Systems

DraftKings

Duke Energy

Barrick Gold

Occidental Petroleum

The second-quarter earnings reporting season may have peaked, but it is not over yet.

Applied Materials, Barrick, Cisco, DraftKings and More Major Earnings Coming This Week

Biohaven Pharmaceutical Hld

Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications

Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million

Merck

Pfizer

The biopharmaceutical industry has been one of the most resilient in dealing with the coronavirus pandemic.

5 Large Biotechs and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-19

NEW YORK, Aug.  03, 2020  (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced the appointments of Henry A. Fernandez and Ted W. Love, M.D. to the company's Board of Directors, effective immediately. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc., a leading global provider of investment decision support tools. Dr. Love is President and Chief Executive Officer of Global Blood Therapeutics, a biopharmaceutical company focused on the treatment and care of sickle cell disease.

Royalty Pharma Appoints Henry A. Fernandez and Ted W.

NEW YORK, July  20, 2020  (GLOBE NEWSWIRE) -- Royalty Pharma (NASDAQ: RPRX) today announced that it will report its second quarter 2020 financial results on Wednesday, August 12, 2020, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:00 AM Eastern Time that day.

Royalty Pharma to Announce Second-Quarter 2020 Financial Results on August 12

NEW YORK, July  20, 2020  (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty interest in risdiplam for a one-time payment of $650 million.

Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics

Livongo Health Inc

Reynolds Consumer Products

Warner Music Group

The Renaissance IPO Index is up 37.7% year to date compared to -1.3% for the S&P 500. Here are seven new stocks to buy from this index.

7 New Stocks to Buy for 2021 and Beyond

Potential Royalty Pharma investors should wait until well after the lock-up period expires to buy RPRX stock.

RPRX Will Have a Low Yield Until the Lock-Up Ends

Recent IPO by Royalty Pharma which acquires ownership interests in drug royalties is getting a lot of interest on Wall Street. Long-term investors may want to keep a close eye on RPRX stock
The post Royalty Pharma Stock Is Likely to Reach New Highs in the Coming Years appeared first on InvestorPlace.

News for Royalty Pharma Stock (RPRX)